VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+25.81%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$241M
AUM Growth
+$50.3M
(+26%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
4.82%
Top 10 Holdings %
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17
Top Buys
| 1 |
Brookfield Renewable
BEPC
|
$1.83M |
| 2 |
Western Midstream Partners
WES
|
$1.11M |
| 3 |
Delek US
DK
|
$829K |
| 4 |
Viper Energy
VNOM
|
$789K |
| 5 |
Oneok
OKE
|
$751K |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$1.61M |
| 2 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$1.13M |
| 3 |
AIV
Aimco
AIV
|
$1.11M |
| 4 |
Telefônica Brasil
VIV
|
$1.01M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$988K |
Sector Composition
| 1 | Healthcare | 29.53% |
| 2 | Real Estate | 18.96% |
| 3 | Energy | 16.61% |
| 4 | Materials | 11.31% |
| 5 | Utilities | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Neurocrine Biosciences
NBIX
$13.6B
| $624K | 0.26% |
6,512
+1,421
| +28% | +$136K |
|
102
Halozyme
HALO
$8.8B
| $621K | 0.26% |
14,543
-11,069
| -43% | -$473K |
|
|
GBT
103
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $617K | 0.26% |
14,254
+4,926
| +53% | +$213K |
|
104
FS KKR Capital
FSK
$5.06B
| $615K | 0.26% |
37,145
-10,488
| -22% | -$174K |
|
105
Sarepta Therapeutics
SRPT
$1.94B
| $612K | 0.25% |
3,590
-89
| -2% | -$15.2K |
|
106
Vanda Pharmaceuticals
VNDA
$276M
| $612K | 0.25% |
46,602
-8,175
| -15% | -$107K |
|
107
Amgen
AMGN
$153B
| $610K | 0.25% |
2,652
-31
| -1% | -$7.13K |
|
108
Incyte
INCY
$17B
| $610K | 0.25% |
7,011
+663
| +10% | +$57.7K |
|
|
DCPH
109
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $610K | 0.25% |
10,681
+5,003
| +88% | +$286K |
|
110
Biogen
BIIB
$20.6B
| $608K | 0.25% |
2,482
+389
| +19% | +$95.3K |
|
|
ALXN
111
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $608K | 0.25% |
3,894
-1,453
| -27% | -$227K |
|
112
Karyopharm Therapeutics
KPTI
$60.4M
| $605K | 0.25% |
2,606
+273
| +12% | +$63.4K |
|
113
Enanta Pharmaceuticals
ENTA
$192M
| $603K | 0.25% |
14,321
+2,275
| +19% | +$95.8K |
|
|
BHVN
114
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $600K | 0.25% |
6,997
+2,326
| +50% | +$199K |
|
|
XLRN
115
DELISTED
Acceleron Pharma Inc.
XLRN
| $599K | 0.25% |
4,681
-1,448
| -24% | -$185K |
|
116
Alnylam Pharmaceuticals
ALNY
$59.6B
| $596K | 0.25% |
4,587
-75
| -2% | -$9.75K |
|
117
Ligand Pharmaceuticals
LGND
$3.26B
| $595K | 0.25% |
9,584
+1,002
| +12% | +$62.2K |
|
118
Exelixis
EXEL
$10.1B
| $594K | 0.25% |
29,602
+3,498
| +13% | +$70.2K |
|
119
Gilead Sciences
GILD
$140B
| $593K | 0.25% |
10,171
+2,179
| +27% | +$127K |
|
120
Amicus Therapeutics
FOLD
$2.44B
| $588K | 0.24% |
25,487
-27,987
| -52% | -$646K |
|
121
Nektar Therapeutics
NKTR
$647M
| $587K | 0.24% |
2,300
+398
| +21% | +$102K |
|
122
Regeneron Pharmaceuticals
REGN
$60.2B
| $587K | 0.24% |
1,216
+222
| +22% | +$107K |
|
123
MidCap Financial Investment
MFIC
$1.21B
| $583K | 0.24% |
54,894
-28,598
| -34% | -$304K |
|
|
BPMC
124
DELISTED
Blueprint Medicines
BPMC
| $582K | 0.24% |
5,188
-3,174
| -38% | -$356K |
|
125
Y-mAbs Therapeutics
YMAB
$390M
| $577K | 0.24% |
11,662
+4,353
| +60% | +$215K |
|